|
Measuring patient and carer outcomes from genome sequencing for rare disease diagnosis: A critical appraisal of validated outcome measurement instruments and their psychometric properties
Measuring patient and carer outcomes from genome sequencing for rare disease diagnosis: A critical appraisal of validated outcome measurement instruments and their psychometric properties
|
Sally Sansom,
Sarah Wordsworth,
Michele Peters
|
|
Exploring patient and carer expectations, experiences, and preferences of/for outcomes from genome sequencing for rare disease diagnosis: A qualitative outcomes model validation study
Exploring patient and carer expectations, experiences, and preferences of/for outcomes from genome sequencing for rare disease diagnosis: A qualitative outcomes model validation study
|
Sally Sansom,
Sarah Wordsworth,
Michele Peters
|
|
Evaluating the content validity, construct validity, responsiveness, interpretability, feasibility, and acceptability of outcome measurement instruments in the context of genome sequencing for rare disease diagnosis: A longitudinal mixed-methods multi-instrument comparison study
Evaluating the content validity, construct validity, responsiveness, interpretability, feasibility, and acceptability of outcome measurement instruments in the context of genome sequencing for rare disease diagnosis: A longitudinal mixed-methods multi-instrument comparison study
|
Sally Sansom,
Sarah Wordsworth,
Michele Peters
|
|
Invest4Health
Invest4Health
|
Sarah Wordsworth,
Rositsa Koleva-Kolarova
|
|
MRC Centre of Research Excellence in Therapeutic Genomics
MRC Centre of Research Excellence in Therapeutic Genomics
|
Sarah Wordsworth,
Liz Morrell,
Fred McElwee
|
|
The cost and cost-effectiveness of whole-exome and whole-genome sequencing: A systematic literature review
The cost and cost-effectiveness of whole-exome and whole-genome sequencing: A systematic literature review
|
Fred McElwee,
Sarah Wordsworth,
Sally Sansom
|
|
Discrete choice experiment to determine what levels of reimbursement and financial incentive lead to the greatest uptake amongst UK GPs of a diagnostic test to inform antibiotic prescribing
Discrete choice experiment to determine what levels of reimbursement and financial incentive lead to the greatest uptake amongst UK GPs of a diagnostic test to inform antibiotic prescribing
|
Sarah Wordsworth,
Madison Luick,
David Eyre
|
|
Aggressive Infection-Related East Africa Lymphoma (AI-REAL) project
Aggressive Infection-Related East Africa Lymphoma (AI-REAL) project
|
Sarah Wordsworth,
Liz Morrell
|
|
Addressing the health economic challenges of evaluating genome-targeted therapies with uncertain costs and benefits
Addressing the health economic challenges of evaluating genome-targeted therapies with uncertain costs and benefits
|
Fred McElwee,
Sarah Wordsworth
|
|
AMULET: Abbreviated Magnetic Resonance Imaging vs ultrasound surveillance for liver cancer detection in people at high risk of developing liver cancer
AMULET: Abbreviated Magnetic Resonance Imaging vs ultrasound surveillance for liver cancer detection in people at high risk of developing liver cancer
|
Sarah Wordsworth
|
|
Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness (ASTUTE) Trial
Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness (ASTUTE) Trial
|
Sarah Wordsworth,
Xuemin Zhu,
Rositsa Koleva-Kolarova
|
|
The By-Band-Sleeve study
The By-Band-Sleeve study
|
Sarah Wordsworth,
Rositsa Koleva-Kolarova
|
|
Combining infectious disease and economic modelling to inform decision‑making around antibiotic use targets and implementation of interventions
Combining infectious disease and economic modelling to inform decision‑making around antibiotic use targets and implementation of interventions
|
Sarah Wordsworth,
Madison Luick
|
|
Economic analysis of multiple myeloma cancer panel
Economic analysis of multiple myeloma cancer panel
|
Sarah Wordsworth,
Liz Morrell,
Fred McElwee
|
|
Evaluating the full costs and effects of high-price, disease-modifying therapies
Evaluating the full costs and effects of high-price, disease-modifying therapies
|
Fred McElwee,
Sarah Wordsworth
|
|
HEcoPerMed: Health Economic Models for Personalised Medicine
HEcoPerMed: Health Economic Models for Personalised Medicine
|
Sarah Wordsworth,
Rositsa Koleva-Kolarova
|
|
Measuring patient and carer outcomes from genome sequencing: A systematic review of outcome measurement instruments
Measuring patient and carer outcomes from genome sequencing: A systematic review of outcome measurement instruments
|
Sally Sansom,
Sarah Wordsworth,
Michele Peters
|
